SLIT and NTRK like family member 2Genealiases: CXorf1 · CXorf2 · SLITL1 · TMEM257 · XLID111
Q-omics provides the consensus-scored SLITRK2 profile across patient tissues and cancer cell-line models. SLITRK2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLITRK2 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, SLITRK2 RNA expression shows 16,414 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LUAD as cancer lineages where SLITRK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLITRK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLITRK2 survival associations across molecular data types. SLITRK2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLITRK2 RNA expression–survival associations across cancer types. High SLITRK2 expression shows unfavorable associations in UVM, KIRC, SCLC, UCEC, STAD and ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLITRK2 RNA expression.
This table summarizes SLITRK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SLITRK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLITRK2 shows lower tumor expression in LUAD, THCA, KICH, COAD and BLCA and higher tumor expression in KIRP. The LUAD box plot shows higher SLITRK2 RNA expression in normal versus tumor tissue (log2 FC = −0.875, t-test p < 0.001).
This table shows molecular features associated with SLITRK2 in patient tissues and cancer cell lines. In patient samples, SLITRK2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLITRK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
